奥泰生物
(688606)
| 流通市值：39.48亿 | | | 总市值：39.48亿 |
| 流通股本：7928.09万 | | | 总股本：7928.09万 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 195,372,450.28 | 905,344,393.81 | 633,076,568.3 | 429,850,024.75 |
| 营业收入 | 195,372,450.28 | 905,344,393.81 | 633,076,568.3 | 429,850,024.75 |
| 二、营业总成本 | 178,180,947.39 | 711,573,116.92 | 457,636,927.5 | 299,110,577.78 |
| 营业成本 | 91,989,354.41 | 444,092,851.5 | 277,209,577.75 | 186,926,166.19 |
| 税金及附加 | 6,092,176.39 | 9,545,644.5 | 4,379,227.65 | 4,039,473.17 |
| 销售费用 | 16,791,367.7 | 79,315,434.57 | 59,896,478.03 | 38,436,383.21 |
| 管理费用 | 19,679,078.01 | 79,749,015.03 | 54,308,035.1 | 34,605,227.94 |
| 研发费用 | 28,746,985.17 | 109,316,439.07 | 74,216,918.14 | 48,195,711.85 |
| 财务费用 | 14,881,985.71 | -10,446,267.75 | -12,373,309.17 | -13,092,384.58 |
| 其中:利息费用 | 206,798.03 | 280,377.88 | 224,732.93 | 100,232.85 |
| 其中:利息收入 | 4,475,913.87 | 25,494,862.47 | 18,003,219.62 | 13,241,292.78 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 5,618,393.47 | 40,611,636.15 | 18,960,527.98 | 15,823,882.7 |
| 加:投资收益 | 726,239.24 | 335,646.32 | 8,831,717.6 | 6,084,326.45 |
| 资产处置收益 | 65,044.06 | 616,679.63 | 616,679.63 | - |
| 资产减值损失(新) | -50,597.96 | -4,261,937.03 | -608,005.17 | -608,005.17 |
| 信用减值损失(新) | -3,319,223.51 | -3,176,624.43 | -7,250,968.48 | -4,996,527.44 |
| 其他收益 | 1,412,309.92 | 23,913,422.32 | 22,818,985.29 | 5,537,749.4 |
| 四、营业利润 | 21,643,668.11 | 251,810,099.85 | 218,808,577.65 | 152,580,872.91 |
| 加:营业外收入 | 172,124.11 | 452.66 | 277.3 | 0.3 |
| 减:营业外支出 | 55,869.09 | 633,883.47 | 562,891.71 | 473,485.47 |
| 五、利润总额 | 21,759,923.13 | 251,176,669.04 | 218,245,963.24 | 152,107,387.74 |
| 减:所得税费用 | 2,628,934.73 | 31,104,761.64 | 28,522,829.07 | 20,005,582.88 |
| 六、净利润 | 19,130,988.4 | 220,071,907.4 | 189,723,134.17 | 132,101,804.86 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 19,130,988.4 | 220,071,907.4 | 189,723,134.17 | 132,101,804.86 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 19,394,345.33 | 220,191,901.65 | 189,809,703.81 | 132,012,694.61 |
| 少数股东损益 | -263,356.93 | -119,994.25 | -86,569.64 | 89,110.25 |
| 扣除非经常损益后的净利润 | 11,772,864.62 | 157,141,091.91 | 147,068,606.58 | 109,435,369.36 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.24 | 2.78 | 2.39 | 1.67 |
| (二)稀释每股收益 | 0.24 | 2.78 | 2.39 | 1.67 |
| 八、其他综合收益 | 308,042.58 | -361,475.92 | -608,935.67 | -647,348.27 |
| 归属于母公司股东的其他综合收益 | 301,101.44 | -330,302.5 | -610,326.63 | -644,840.25 |
| 九、综合收益总额 | 19,439,030.98 | 219,710,431.48 | 189,114,198.5 | 131,454,456.59 |
| 归属于母公司股东的综合收益总额 | 19,695,446.77 | 219,861,599.15 | 189,199,377.18 | 131,367,854.36 |
| 归属于少数股东的综合收益总额 | -256,415.79 | -151,167.67 | -85,178.68 | 86,602.23 |
| 公告日期 | 2026-04-20 | 2026-04-20 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |